Varox

Rivaroxaban INN

Composition :

Varox :Each film coated tablet contains Rivaroxaban INN 2.5 mg.

Varox-10 : Each film coated tablet contains Rivaroxaban INN 10 mg

Indications : Varox : The medicine is indicated for the prevention of atherothrombotic events in adult patients after an Acute Coronary Syndrome (ACS) with elevated cardic biomarkers (Troponin or CK-MB). It is co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine.

Varox-10 :Prevention of venous thromboembolism (VTE) in adult patientsundergoing elective hip or knee replacement surgery. Treatment of DVT, PE & extendedtreatment of prevention of recurrent DVT & PE in adult.Reduction in Risk of Stroke & Systemic Embolism in Non valvular Atrial Fibrillation.

Dosage and administration : Varox :The recommended dose is 2.5 mg twice daily, Patients should also take a daily dose 75- 100 mg Aspirin or a daily of 75-100mg aspirin in addition to either a daily dose of 75 mg clopidogrel or a standard daily dose of ticlopidine. Treatment with Varox should be started as soon as possible after stabilization of the ACS event; at the earliest 24 hours after admission to hospital & at the time when parenteral anticoagulation therapy would normally be dicontinued.

Varox-10 : See the full Medicine Description.Or, as directed by the registered physicians.

Use in Pregnancy and lactation : Pregnancy category C. There is no adequate or well-controlled studies of Rivaroxaban in pregnant women, It should be used with caution in pregnant women only if the potential benefit justifies the potential risk to the mother & fetus. It is not known if Rivaroxaban is excreted in human milk. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Packing : Varox : Each box contains 2 x 14's tablets in blister pack.

Varox-10 : Each box contains 1 x 14's tablets in blister pack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2019 Designed and Developed by ATI Limited.